Telomerase Peptide Vaccine Shows Promising Long-Term Survival in Men with Metastatic Prostate Cancer

This was long-term clinical monitoring of a phase I/II study. Twenty-two men with high-grade (ISUP 4-5) de novo metastatic prostate cancer (lymph node and/or bone metastases) received the UV1 hTERT peptide vaccine combined with androgen deprivation therapy (ADT) and radiotherapy between January 2013 and July 2014. Immune responses were monitored before, during, and after vaccination, then every 6 months until PSA progression. MRI was performed at baseline, 6 months, 1 year, 2 years, and at progression.

Metastatic prostate cancer diagnosed at presentation carries a poor prognosis, with median survival typically around 4-5 years with standard therapy. The 62-month median overall survival and 84-month cancer-specific survival observed here are encouraging, particularly for a disease historically considered resistant to immunotherapy. The finding that immune response predicts survival provides a potential biomarker for identifying which patients benefit most from vaccination, moving toward personalized treatment strategies.

Cancer vaccines targeting telomerase represent an elegant therapeutic strategy — telomerase is reactivated in approximately 85% of cancers but is largely silent in normal adult cells, making it an attractive tumor antigen. UV1 is one of several telomerase-targeting peptide vaccines in development. This long-term follow-up adds to growing evidence that immunotherapy can play a role in prostate cancer, a cancer type that has seen limited success with checkpoint inhibitors. The biomarker finding — that immune response independently predicts survival — supports the broader precision immunotherapy paradigm.

This is a small single-arm phase I/II study with only 22 patients and no control group, making it impossible to definitively attribute the survival results to the vaccine versus the combination of ADT and radiotherapy. The standard of care for metastatic prostate cancer has evolved since the trial began in 2013. The long follow-up period introduces survivor bias — patients alive at later time points may have had inherently less aggressive disease. External validation in a randomized controlled trial is needed.